Finance Watch: Public Market Doldrums Have Not Sunk Private Company Funding Yet
Venture Capital Kept Up Near-Record Pace In Q1
ARCH closed a $3bn VC fund to end the month of June while in the same week six public biopharma firms said they are cutting jobs. Even so, some publicly traded companies have been able to launch sizeable offerings, including a $450m note sale by Cytokinetics and Xenon’s $250m follow-on.
